Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System

Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System

<b>Background/Objectives</b>: Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies. We aimed to assess variation in the initiation of infliximab biosimilars in a large pediatric cohort. <b>Met...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ross M. Maltz, Shehzad A. Saeed, Jeremy Adler
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Children
Subjects:	ImproveCareNow anti-TNF inflammatory bowel disease
Online Access:	https://www.mdpi.com/2227-9067/12/5/656
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
by: Magdalena Kaniewska, et al.
Published: (2020-11-01)

Commentary: Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
by: Yingjie Liu, et al.
Published: (2025-07-01)

Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice
by: Dorota Waz, et al.
Published: (2025-01-01)

Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study
by: Horng-Yih Chiu, et al.
Published: (2024-12-01)

Cutaneous Kaposi’s Sarcoma Following Long-Term Infliximab Treatment in a Patient with HIV-Negative Antibiotic-Dependent Chronic Pouchitis: Considerations on an Exceptional Finding
by: Raffaele Pellegrino, et al.
Published: (2024-12-01)

Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn’s disease
by: Yoon Zi Kim, et al.
Published: (2025-07-01)

Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study
by: Abdulhamid Alhadab, et al.
Published: (2025-03-01)

Prevalence and clinical implications of anti-drug antibody formation and serum drug levels among patients with IBD receiving anti-TNF therapy: A cross-sectional study
by: Ahmed Alghamdi, et al.
Published: (2025-03-01)

Beyond Suppression: Peripheral T Cell Responses to Vaccination in Inflammatory Bowel Disease Patients Undergoing Anti-Tumor-Necrosis-Factor Therapy
by: Martin Qui, et al.
Published: (2024-11-01)

Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database
by: Yanhong Deng, et al.
Published: (2025-08-01)

Colonic strictures in Crohn’s disease: a non-surgical survival
by: Sarra Laabidi, et al.
Published: (2025-12-01)

Primary Gastrointestinal EBV‐Associated Classical Hodgkin Lymphoma in Crohn Disease on Anti‐TNF‐α Therapy: A Rare Association
by: Katrina Collins, et al.
Published: (2025-04-01)

Patent and Regulatory Landscape of Biosimilars in the United States and Europe: Implications for Advancing the Domestic Biosimilar Industry with a Focus on Anti-TNF-α Biopharmaceuticals
by: Tae-Kwon Kim, et al.
Published: (2025-06-01)

Infliximab treatment for Cronkhite-Canada syndrome in pregnancy: A case report
by: Ayano Rosemary Nakamura, et al.
Published: (2025-06-01)

Comparative efficacy and safety of vedolizumab and antitumor necrosis factor alfa in patients with inflammatory bowel diseases: A meta‑analysis
by: Li Yafang, et al.
Published: (2025-03-01)

Comparative Role of Anti-TNF Agents versus IL-12/23 Inhibitors in Inflammatory Bowel Disease: An Updated Review
by: Xue Bin Leong, et al.
Published: (2024-12-01)

The total gut mucosal and fecal bacterial load increases in successful treatment of inflammatory bowel disease with infliximab
by: Rebecka Ventin-Holmberg, et al.
Published: (2025-08-01)

Optimizing development of anti-TNFα biosimilars based on 10 years’ experience
by: Cecil Nick
Published: (2025-02-01)

Aseptic abscess syndrome: a case report of a patient achieving remission with both infliximab originator and biosimilar administered at varied intervals
by: Federica Maria Ucci, et al.
Published: (2024-12-01)

Therapeutic potential of Leea asiatica: Chemical isolation and validation of ethnomedicinal claims through in vitro and in silico assessment of antioxidant and anti-inflammatory properties
by: Khem Raj Joshi, et al.
Published: (2024-10-01)

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study
by: Fanny Alcira Reyes Neira, et al.
Published: (2025-02-01)

El papel de los biosimilares en la enfermedad inflamatoria intestinal: una realidad en nuestro país
by: Juan Ricardo Márquez Velásquez, et al.
Published: (2017-12-01)

XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel Disease
by: Simon Woelfel, et al.
Published: (2025-07-01)

The effect of coffee consumption on the tnf-α level after submaximal exercise
by: Izzul Mujahidin, et al.
Published: (2025-04-01)

The effect of coffee consumption on the tnf-α level after submaximal exercise
by: Izzul Mujahidin, et al.
Published: (2025-04-01)

Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients
by: Luisa Leite Barros, et al.
Published: (2024-12-01)

Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort Study
by: Ancona S, et al.
Published: (2025-04-01)

Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study
by: Susana Clemente Bautista, et al.
Published: (2024-12-01)

Case Report: Facial Malassezia folliculitis following infliximab treatment in Crohn’s disease
by: Liji Chen, et al.
Published: (2025-08-01)

Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
by: Joo Hye Song, et al.
Published: (2025-05-01)

Infliximab in Inflammatory Bowel Disease: Leveraging Physiologically Based Pharmacokinetic Modeling in the Clinical Context
by: Zvonimir Petric, et al.
Published: (2024-09-01)

TNF-?, cukrzyca typu 1 i limfocyty T regulatorowe
by: Monika Ryba, et al.
Published: (2010-12-01)

Anti-TNFα and Anti-IL-1β Monoclonal Antibodies Preserve BV-2 Microglial Homeostasis Under Hypoxia by Mitigating Inflammatory Reactivity and ATF4/MAPK-Mediated Apoptosis
by: Linglin Zhang, et al.
Published: (2025-03-01)

Cerebrovascular Thrombosis in Pediatric Ulcerative Colitis: A Case Report
by: Naire Sansotta, et al.
Published: (2025-02-01)

Treatment of ankylosing spondylitis during pregnancy
by: O. A. Krichevskaya, et al.
Published: (2021-07-01)

The Potential of Ethanol Extract of Aleurites Moluccanus Leaves as TNF-α Inhibitor in Oral Incision Wound Care Model
by: Elfi Zahara, et al.
Published: (2024-12-01)

Awangarda jako software
by: Lev Manovich
Published: (2001-12-01)

Utility of the aspirin and P2Y12 response assays to determine the effects of antiplatelet agents in patients with subdural hematoma undergoing neurosurgery
by: Ombretta Para, et al.
Published: (2025-07-01)

Potential of Using Walnuts as a Part of Nutritional Therapy for Inflammatory Bowel Diseases
by: Andrew V. Nalyotov, et al.
Published: (2025-02-01)

Assessing the therapeutic potential of rutin in alleviating symptoms of inflammatory bowel disease: a meta-analysis
by: Zhenkai Zou, et al.
Published: (2025-04-01)